{
    "xml": "<topic id=\"PHP3230\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/lofexidine-hydrochloride\" basename=\"lofexidine-hydrochloride\" title=\"LOFEXIDINE HYDROCHLORIDE\">\n<title>LOFEXIDINE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_607\" namespace=\"/interactions/list-of-drug-interactions/lofexidine\">Lofexidine</xref>\n</p>\n<data name=\"vtmid\">349934008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_876717894\" title=\"Anaesthetics (local)\">Anaesthetics (local)</xref>\n</data>\n</data>\r\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_252514551\" title=\"Antiarrhythmics\">Antiarrhythmics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP49445\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Lofexidine is an alpha<sub>2</sub>-adrenergic agonist.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48719\" outputclass=\"indicationsAndDose\" rev=\"1.33\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Management of symptoms of opioid withdrawal</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 800&#8239;micrograms daily in divided doses, increased in steps of 400&#8211;800&#8239;micrograms daily (max. per dose 800&#8239;micrograms) as required recommended duration of treatment 7&#8211;10 days if no opioid use (but longer may be required); maximum 2.4&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50011\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Bradycardia</ph>; <ph outputclass=\"caution\">cerebrovascular disease</ph>; <ph outputclass=\"caution\">depression</ph>; <ph outputclass=\"caution\">history of QT prolongation</ph>; <ph outputclass=\"caution\">hypotension (monitor pulse rate and blood pressure)</ph>; <ph outputclass=\"caution\">metabolic disturbances</ph>; <ph outputclass=\"caution\">recent myocardial infarction</ph>; <ph outputclass=\"caution\">severe coronary insufficiency</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48390\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (lofexidine).</p>\n</sectiondiv>\n<sectiondiv>\n<p>Caution with concomitant administration of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37848\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bradycardia</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dry mucous membranes</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">QT-interval prolongation</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48087\" outputclass=\"pregnancy\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if benefit outweighs risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50171\" outputclass=\"breastFeeding\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if benefit outweighs risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47497\" outputclass=\"renalImpairment\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in chronic impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37487\" outputclass=\"monitoringRequirements\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitoring of blood pressure and pulse rate is recommended on initiation, for at least 72 hours or until a stable dose is achieved, and on discontinuation. </p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37668\" outputclass=\"treatmentCessation\" rev=\"1.11\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Treatment should be withdrawn gradually over 2&#8211;4 days (or longer) to reduce the risk of rebound hypertension and associated symptoms.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57936\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.13\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Lofexidine has been used in children over 12 years in the management of symptoms of opioid withdrawal.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47759\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>The patient should take part of the dose at bedtime to offset insomnia associated with opioid withdrawal.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3230-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/lofexidine-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76649\" title=\"Tablet\" namespace=\"/drugs/lofexidine-hydrochloride/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"2\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"4\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_607\" namespace=\"/interactions/list-of-drug-interactions/lofexidine\" title=\"Lofexidine\" count=\"1\" rel=\"link\">Lofexidine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76649\" namespace=\"/drugs/lofexidine-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP3230",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/lofexidine-hydrochloride",
    "basename": "lofexidine-hydrochloride",
    "title": "LOFEXIDINE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_607",
            "label": "Lofexidine"
        }
    ],
    "vtmid": "349934008",
    "drugClassification": [
        "Anaesthetics (local)",
        "Antiarrhythmics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Lofexidine is an alpha2-adrenergic agonist.",
                "html": "<p>Lofexidine is an alpha<sub>2</sub>-adrenergic agonist.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Management of symptoms of opioid withdrawal",
                        "html": "Management of symptoms of opioid withdrawal"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 800 micrograms daily in divided doses, increased in steps of 400&#8211;800 micrograms daily (max. per dose 800 micrograms) as required recommended duration of treatment 7&#8211;10 days if no opioid use (but longer may be required); maximum 2.4 mg per day.",
                        "html": "<p>Initially 800&#8239;micrograms daily in divided doses, increased in steps of 400&#8211;800&#8239;micrograms daily (max. per dose 800&#8239;micrograms) as required recommended duration of treatment 7&#8211;10 days if no opioid use (but longer may be required); maximum 2.4&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Bradycardia",
                "html": "Bradycardia"
            },
            {
                "type": "cautions",
                "textContent": "cerebrovascular disease",
                "html": "cerebrovascular disease"
            },
            {
                "type": "cautions",
                "textContent": "depression",
                "html": "depression"
            },
            {
                "type": "cautions",
                "textContent": "history of QT prolongation",
                "html": "history of QT prolongation"
            },
            {
                "type": "cautions",
                "textContent": "hypotension (monitor pulse rate and blood pressure)",
                "html": "hypotension (monitor pulse rate and blood pressure)"
            },
            {
                "type": "cautions",
                "textContent": "metabolic disturbances",
                "html": "metabolic disturbances"
            },
            {
                "type": "cautions",
                "textContent": "recent myocardial infarction",
                "html": "recent myocardial infarction"
            },
            {
                "type": "cautions",
                "textContent": "severe coronary insufficiency",
                "html": "severe coronary insufficiency"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (lofexidine).",
                "html": "<p>Appendix 1 (lofexidine).</p>"
            },
            {
                "type": "general",
                "textContent": "Caution with concomitant administration of drugs that prolong QT interval.",
                "html": "<p>Caution with concomitant administration of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Bradycardia",
                        "html": "Bradycardia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dry mucous membranes",
                        "html": "dry mucous membranes",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "QT-interval prolongation",
                        "html": "QT-interval prolongation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if benefit outweighs risk&#8212;no information available.",
                "html": "<p>Use only if benefit outweighs risk&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if benefit outweighs risk&#8212;no information available.",
                "html": "<p>Use only if benefit outweighs risk&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in chronic impairment.",
                "html": "<p>Caution in chronic impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitoring of blood pressure and pulse rate is recommended on initiation, for at least 72 hours or until a stable dose is achieved, and on discontinuation.",
                "html": "<p>Monitoring of blood pressure and pulse rate is recommended on initiation, for at least 72 hours or until a stable dose is achieved, and on discontinuation. </p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Treatment should be withdrawn gradually over 2&#8211;4 days (or longer) to reduce the risk of rebound hypertension and associated symptoms.",
                "html": "<p>Treatment should be withdrawn gradually over 2&#8211;4 days (or longer) to reduce the risk of rebound hypertension and associated symptoms.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Lofexidine has been used in children over 12 years in the management of symptoms of opioid withdrawal.",
                "html": "<p>Lofexidine has been used in children over 12 years in the management of symptoms of opioid withdrawal.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "The patient should take part of the dose at bedtime to offset insomnia associated with opioid withdrawal.",
                "html": "<p>The patient should take part of the dose at bedtime to offset insomnia associated with opioid withdrawal.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76649",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_607",
                "label": "Lofexidine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76649",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}